Research Radartracking 209 published studies · 52 human · 18 clinical trials · 25 cancer pages · updated Jun 2026Open the Research Map →

Research Radar

New PubMed studies on repurposed drugs and natural compounds in cancer — summarized in plain language and reviewed by a person before posting.

How to read this page. These studies are automatically collected from PubMed and summarized by AI from the abstract, then reviewed by a human before publishing. Each summary describes only what that study reported — most are early lab, animal, or small human studies, and findings often conflict. This is educational information, not medical advice, and not a recommendation to take anything. Always talk with your oncologist.
Topic tags. Each study is filed under its main topic. Anticancer studies are the default; these tags flag the other dimensions:
Safety — Safety & interactionsAbsorption (PK) — How it's absorbed (PK)Formulation — Formulation & deliverySupportive care — Symptom & supportive careMetabolism — Metabolism & pathwaysTrial — Clinical trialMechanism — Biomarker & mechanism
Showing studies that mention “mesonephric adenocarcinoma”.
3 of 200 studies
Human · observationalMechanismReported positiveLimited evidenceTier 3 · early humann = 48

Napsin-A Expression in Mesonephric and Mesonephric-like Adenocarcinomas: Implications for Distinction From Clear Cell Carcinoma

International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists · Nov 2025 · case series

mesonephric adenocarcinomamesonephric-like adenocarcinomaclear cell carcinomamesonephric carcinosarcoma

The authors performed Napsin-A immunohistochemistry on whole-slide sections from 48 mesonephric and mesonephric-like adenocarcinomas and carcinosarcomas. Napsin-A was positive in 17/48 cases (35.4%), with focal granular cytoplasmic staining in 1–40% of cells; positivity occurred in 13/32 MLAs, 2/13 MAs, and 2/3 carcinosarcomas. The study concludes that Napsin-A is expressed in a substantial subset of these tumors and that reliance on a single marker could lead to misclassification as clear cell carcinoma.

Reported effects: Napsin-A positive overall 35.4%, n=48 · Range of focal granular cytoplasmic expression · +3 more

Key findings
  • Napsin-A staining was positive in 17 of 48 cases (35.4%), with focal granular cytoplasmic expression ranging from 1% to 40%.
  • 13/32 (40.6%) mesonephric-like adenocarcinomas (MLAs) were Napsin-A positive.
  • 2/13 (15.4%) mesonephric adenocarcinomas (MAs) were Napsin-A positive.
  • 2/3 (66.7%) mesonephric or mesonephric-like carcinosarcomas were Napsin-A positive.
  • Because of morphologic and immunohistochemical overlap, Napsin-A expression in MA/MLA may contribute to misclassification as clear cell carcinoma.
Limitations: Observational pathology series without reported clinical outcome correlation; Relatively small overall sample size and very small subgroup sizes (e.g., n=3 carcinosarcomas); Findings are based solely on immunohistochemistry on tissue sections; no clinical or molecular correlation reported in the abstract.

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed

Human · observationalMechanismReported positiveLimited evidenceTier 3 · early humann = 6

Mesonephric Adenocarcinoma and Mesonephric-like Adenocarcinoma of the Urinary Tract

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · Jan 2023 · case series

mesonephric adenocarcinomamesonephric-like adenocarcinomaurinary tracturinary bladderperirenal regionureteruterine cervixovaryendometrium

This study reports a case series of six mesonephric (MA) or mesonephric-like (MLA) adenocarcinomas arising in the urinary tract and describes their morphology, immunophenotype, and limited molecular findings. All six tumors were Pax8-positive and showed a luminal pattern of CD10 staining (CD10 unavailable in one case); a KRAS G12C mutation was found in one case, and other tested hotspot mutations were absent. The authors propose classifying urinary-tract tumors with mesonephric remnants as MA and those associated with Müllerian-type precursors as MLA.

Reported effects: MA in urinary bladder cases 4, n=6 · MA in perirenal region cases 1, n=6 · +4 more

Key findings
  • Characterized 4 cases of MA in the urinary bladder (1 woman and 3 men), 1 case of MA in the perirenal region (woman), and 1 case of MLA in the ureter (woman).
  • All cases (6/6) were diffusely positive for Pax8.
  • All displayed a luminal pattern of CD10 staining, except case 4 for which CD10 immunostain was not available for review.
  • GATA3 expression was variable: focally positive in cases 1, 2, and 6; negative in case 3; diffusely positive in case 5.
  • TTF-1 was diffusely expressed in cases 1 and 3 and negative in cases 2, 5, and 6.
  • A KRAS G12C somatic mutation was detected in case 6; hotspot mutations in KRAS, NRAS, and PIK3CA were not present in other tested cases.
  • Authors conclude urinary-tract MAs and MLAs share morphology and immunophenotype with their counterparts in the female genital tract and propose a classification based on origin (mesonephric remnants/Wolffian vs Müllerian-type precursors).
Limitations: Very small number of cases (n=6).; Retrospective case series without systematic clinical outcome or follow-up data reported.; Molecular testing appears limited (hotspot testing reported) and not uniformly applied to all cases.; One case lacked CD10 immunostain availability, limiting uniform immunophenotypic assessment..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed

Human · observationalReported negativeModerate evidenceTier 3 · early humann = 99

Clinicopathologic Characteristics of Mesonephric Adenocarcinomas and Mesonephric-like Adenocarcinomas in the Gynecologic Tract: A Multi-institutional Study

The American journal of surgical pathology · Apr 2021 · multi-institutional case series

mesonephric adenocarcinoma (uterine cervix)mesonephric-like adenocarcinoma (endometrium)mesonephric-like adenocarcinoma (ovary)

This multi-institutional study reviewed 99 well-defined cases of mesonephric and mesonephric-like adenocarcinomas of the gynecologic tract and described clinicopathologic features. Most tumors presented at an advanced stage and over half developed recurrences, which were most often distant. Five-year disease-specific survival was 74% for cervical MA, 72% for endometrial MLA, and 71% for ovarian MLA.

Reported effects: advanced stage (II to IV) presentation, MA of the cervix 60%, n=25 · advanced stage (II to IV) presentation, MLA of the endometrium 58%, n=43 · +11 more

Key findings
  • Majority presented at advanced stage (II to IV): 15/25 (60%) MA of the cervix, 25/43 (58%) MLA of the endometrium, and 7/18 (39%) MLA of the ovary.
  • Overall recurrence occurred in 46/89 (52%) of cases.
  • Recurrence rates by site: 12/24 (50%) MA of the cervix, 24/41 (59%) MLA of the endometrium, and 10/24 (42%) MLA of the ovary.
  • When recurrence occurred, it was most commonly distant: 9/12 (75%) MA of the cervix, 22/24 (92%) MLA of the endometrium, and 5/9 (56%) MLA of the ovary.
  • Five-year disease-specific survival was 74% (n=26) for MA of the cervix, 72% (n=43) for MLA of the endometrium, and 71% (n=23) for MLA of the ovary.
  • The authors conclude mesonephric neoplasms are a clinically aggressive group with a predilection for pulmonary recurrence.
Limitations: Observational case series design with potential selection bias inherent to retrospective multi-institutional cohorts.; Subgroup sample sizes are small for some analyses (for example ovarian MLA denominators of 18-24 cases), limiting precision.; Abstract does not report treatment details, follow-up duration, or statistical analyses.; No control or comparator group reported..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text